Drug Trial Radar · NCT07720596
Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,795,570
Actual
Start
Jan 1, 2022
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Charles University, Czech RepublicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institute of Health Information and Statistics of the Czech Republic
- First posted
- Jul 22, 2026
Design
- Study type
- Observational
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This retrospective real-world target trial emulation uses complete Czech nationwide registry data to evaluate whether molnupiravir treatment is associated with lower COVID-19 mortality during the Omicron era. The study compares adults with confirmed acute COVID-19 treated with molnupiravir in addition to standard care versus matched controls treated with standard care without molnupiravir. Patients are followed for three months from time zero, and primary endpoints are the COVID-19 case fatality rate and all-cause mortality.
Conditions
- COVID-19
- SARS-CoV-2
Interventions
MolnupiravirDrug
800 mg of molnupiravir administered twice daily, i.e., four capsules every 12 hours for five days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- COVID-19 CFR comparing patients treated with molnupiravir versus those not treated with molnupiravir.Time frame: Three months from time zero.
- ACM comparing patients treated with molnupiravir versus those not treated with molnupiravir.Time frame: Three months from time zero.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Pharmacology, Third Faculty of Medicine, Charles University
Prague, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.